Aromatase inhibitors plus GnRH a are active in HR +ve premenopausal breast cancer.
Adjuvant exemestane clearly outperforms tamoxifen in high-risk and young women.
Degree of ovarian suppression may be crucial for aromatase inhibitors activity.
Monitoring estradiol upon AI therapy may be useful in young chemotherapy-naïve women.